NASDAQ:ALMR

Alamar Biosciences (ALMR) Stock Price, News & Analysis

$28.68 -1.83 (-6.00%)
As of 11/19/2026 04:00 PM Eastern

About Alamar Biosciences Stock (NASDAQ:ALMR)

Advanced

Key Stats

Today's Range
$28.53
▼
$31.48
50-Day Range
$23.52
▼
$38.13
52-Week Range
$18.84
▼
$39.61
Volume
326,540 shs
Average Volume
733,057 shs
Market Capitalization
$1.99 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.00
Consensus Rating
Moderate Buy

Company Overview

Alamar Biosciences is a life sciences tools company that develops technologies for measuring proteins in biological samples. Its products are designed to help researchers study disease biology and support the development of tools for earlier disease detection and precision medicine.

The company’s offerings include its NULISA platform, which enables sensitive measurement of multiple proteins, and the ARGO HT system, an automated instrument for running assays. Its applications include research into neurodegenerative diseases, cancer and inflammation.

Founded in 2018 and headquartered in Fremont, California, Alamar serves researchers and other organizations working in life sciences and biomedical research.

AI Generated. May Contain Errors.

Alamar Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
56th Percentile Overall Score

ALMR MarketRank™: 
2.82420154185 of 5 stars

Alamar Biosciences scored higher than 56% of companies evaluated by MarketBeat, and ranked 389th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Alamar Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 4 buy ratings, 3 hold ratings, and no sell ratings.

  • Upside Potential

    Alamar Biosciences has a consensus price target of $33.00, representing about 15.1% upside from its current price of $28.68.

  • Amount of Analyst Coverage

    Alamar Biosciences has only been the subject of 2 research reports in the past 90 days.

  • Read more about Alamar Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Alamar Biosciences are expected to grow in the coming year, from ($1.29) to ($1.00) per share.

  • Price to Book Value per Share Ratio

    Alamar Biosciences has a P/B Ratio of 6.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    3.23% of the float of Alamar Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Alamar Biosciences has a short interest ratio ("days to cover") of 3.27, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Alamar Biosciences has recently decreased by 16.19%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Alamar Biosciences does not currently pay a dividend.

  • Dividend Growth

    Alamar Biosciences does not have a long track record of dividend growth.

  • News Sentiment

    Alamar Biosciences has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Alamar Biosciences this week, compared to 4 articles on an average week.
  • Search Interest

    7 people have searched for ALMR on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Alamar Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Alamar Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $47,503,514.00 in company stock.

  • Percentage Held by Institutions

    Alamar Biosciences has minimal institutional ownership at this time.

  • Read more about Alamar Biosciences' insider trading history.
Receive ALMR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alamar Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ALMR Stock News Headlines

Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
See More Headlines

ALMR Stock Analysis - Frequently Asked Questions

Alamar Biosciences' stock was trading at $22.00 on April 17, 2026. Since then, ALMR stock has increased by 30.4% and is now trading at $28.68.

Alamar Biosciences, Inc. (NASDAQ:ALMR) released its earnings results on Wednesday, November, 4th. The company reported ($0.19) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.03. The company had revenue of $33.55 million for the quarter. Alamar Biosciences had a negative trailing twelve-month return on equity of 78.71% and a negative net margin of 48.22%.
Read the conference call transcript
.

Alamar Biosciences (ALMR) raised $180 million in an IPO on Friday, April 17th 2026. The company issued 11,250,000 shares at $15.00-$17.00 per share.

Alamar Biosciences's lock-up period expired on Wednesday, October 14th. Alamar Biosciences had issued 11,250,000 shares in its public offering on April 17th. The total size of the offering was $191,250,000 based on an initial share price of $17.00. Since the expiration of Alamar Biosciences' lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.

Alamar Biosciences' top institutional investors include State Street Corp (0.37%), Goldman Sachs Group Inc. (0.19%), Sumitomo Mitsui Trust Group Inc. (0.10%) and Bellevue Group AG (0.05%). Insiders that own company stock include Nicholas Naclerio, Innovation Fund Gp Illumina II and Corporate Gp Vi Ltd Qiming.
View institutional ownership trends
.

Shares of ALMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/04/2026
Today
11/20/2026
Citi Annual Global Healthcare Conference 2026
12/02/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Life Sciences Tools & Services
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:ALMR
CIK
2104204
Employees
222
Year Founded
2018

Price Target and Rating

High Price Target
$36.00
Low Price Target
$27.00
Potential Upside/Downside
+15.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.15)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$29.82 million
Net Margins
-48.22%
Pretax Margin
-47.62%
Return on Equity
-78.71%
Return on Assets
-20.08%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.49
Quick Ratio
7.87

Sales & Book Value

Annual Sales
$74.21 million
Price / Sales
26.85
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.37 per share
Price / Book
6.56

Miscellaneous

Outstanding Shares
69,480,000
Free Float
N/A
Market Cap
$1.99 billion
Optionable
N/A
Beta
N/A

Social Links

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (NASDAQ:ALMR) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners